MLYS vs. SWTX, RNA, RARE, PTGX, AAPG, SRRK, MLTX, MTSR, VKTX, and KYMR
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.
Mineralys Therapeutics vs. Its Competitors
SpringWorks Therapeutics (NASDAQ:SWTX) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.
SpringWorks Therapeutics currently has a consensus target price of $52.57, suggesting a potential upside of 11.88%. Mineralys Therapeutics has a consensus target price of $32.25, suggesting a potential upside of 135.40%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than SpringWorks Therapeutics.
Mineralys Therapeutics has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -115.60%. SpringWorks Therapeutics' return on equity of -51.10% beat Mineralys Therapeutics' return on equity.
84.5% of Mineralys Therapeutics shares are owned by institutional investors. 7.8% of SpringWorks Therapeutics shares are owned by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Mineralys Therapeutics has lower revenue, but higher earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, SpringWorks Therapeutics had 1 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 5 mentions for SpringWorks Therapeutics and 4 mentions for Mineralys Therapeutics. SpringWorks Therapeutics' average media sentiment score of 0.75 beat Mineralys Therapeutics' score of 0.75 indicating that SpringWorks Therapeutics is being referred to more favorably in the media.
SpringWorks Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500.
Summary
Mineralys Therapeutics beats SpringWorks Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mineralys Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLYS) was last updated on 7/2/2025 by MarketBeat.com Staff
